Clinical features of late cytomegalovirus infection after hematopoietic stem cell transplantation

International Journal of Hematology

Volumn 87, Issue 3, 2008, Pages 310-318

  Asano Mori, Yuki ^a,b   Kanda, Yoshinobu ^a   Oshima, Kumi ^a   Kako, Shinichi ^a   Shinohara, Akihito ^a   Nakasone, Hideki ^a   Sato, Hiroyuki ^a   Watanabe, Takuro ^a   Hosoya, Noriko ^c   Izutsu, Koji ^a   Asai, Takashi ^a   Hangaishi, Akira ^a   Motokura, Toru ^a   Chiba, Shigeru ^c   Kurokawa, Mineo ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b JAPANESE RED CROSS MEDICAL CENTER   (Japan)

^c UNIVERSITY OF TOKYO HOSPITAL   (Japan)

Author keywords

Antigenemia; Cytomegalovirus; Ganciclovir; Hematopoietic stem cell transplantation; Preemptive therapy

Indexed keywords

ALEMTUZUMAB; STEROID;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG MEGADOSE; FEMALE; GASTROINTESTINAL DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INCIDENCE; JAPANESE; MAJOR CLINICAL STUDY; MALE; RETINITIS; RISK FACTOR;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; COHORT STUDIES; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 46149109475     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-008-0051-1     Document Type: Article

References (18)

1. Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood. 1996;88:4063-71.
2. Boeckh M, Leisenring W, Riddell SR, et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood. 2003;101:407-14.
3. Einsele H, Hebart H, Kauffmann-Schneider C, et al. Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection. Bone Marrow Transplant. 2000;25:757-63.
4. Nguyen Q, Champlin R, Giralt S, et al. Late cytomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients. Clin Infect Dis. 1999;8:618-23.
5. Krause H, Hebart H, Jahn G, Müller CA, Einsele H. Screening for CMV-specific T cell proliferation to identify patients at risk of developing late onset CMV disease. Bone Marrow Transplant. 1997;19:1111-6.
6. Wolf DG, Lurain NS, Zuckerman T, et al. Emergence of late cytomegalovirus central nervous system disease in hematopoietic stem cell transplant recipients. Blood. 2003;101:463-5.
7. Crippa F, Corey L, Chuang EL, Sale G, Boeckh M. Virological, clinical, and ophthalmologic features of cytomegalovirus retinitis after hematopoietic stem cell transplantation. Clin Infect Dis. 2001;32:214-9.
8. Kanda Y, Mineishi S, Saito T, et al. Pre-emptive therapy against cytomegalovirus (CMV) disease guided by CMV antigenemia assay after allogeneic hematopoietic stem cell transplantation: a single-center experience in Japan. Bone Marrow Transplant 2001;27:437-44.
9. Niiya H, Kanda Y, Saito T, et al. Early full donor myeloid chimerism after reduced-intensity stem cell transplantation using a combination of fludarabine and busulfan. Hematologica 2001;86:1071-4.
10. Kanda Y, Komatsu Y, Akahane M, et al. Graft-versus-tumor effect against advanced pancreatic cancer after allogeneic reduced-intensity stem cell transplantation. Transplantation. 2005;79:821-7.
11. Kanda Y, Oshima K, Asano-Mori Y, et al. In vivo alemtuzumab enables haploidentical HLA-mismatched hematopoietic stem cell transplantation without ex vivo graft manipulation. Transplantation. 2005;79:1351-7.
12. Kurihara T, Hayashi J, Matsuoka T, Ito A. HCMV pp65 antigenemia assay using indirect alkaline phosphatase staining method. Bio Med Res. 1995;16:125-9.
13. Asano-Mori Y, Oshima K, Sakata-Yanagimoto M, et al. High-grade cytomegalovirus antigenemia after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2005;36:813-9.
14. Kanda Y, Mineishi S, Saito T, et al. Response-oriented preemptive therapy against cytomegalovirus disease with low-dose ganciclovir: a prospective evaluation. Transplantation. 2002;73:568-72.
15. Asano-Mori Y, Kanda Y, Oshima K, et al. Pharmacokinetics of ganciclovir in haematopoietic stem cell transplantation recipients with or without renal impairment. J Antimicrob Chemother. 2006;57:1004-7.
16. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695-706.
17. Chakrabarti S, Mackinnon S, Chopra R, et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of alemtuzumab in delaying immune reconstitution. Blood. 2002;99:4357-63.
18. Hakki M, Riddell SR, Storek J, et al. Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation. Blood. 2003;102:3060-7.